Abstract: The disclosed invention is a composition for and a method of seating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

Abstract: In an assembled battery including at least two unit cells provided within a supporter, each unit cell is a thin laminate cell packaged with a laminate, and each unit cell is covered by at least one resin. Thus, the assembled battery has a stable performance without structure breakdown or a fracture of the connection tab even when vibration is applied.

Abstract: Disclosed is a cell with a power-generating element and an outer package. The power-generating element includes a unit cell layer including a first electrode, a second electrode and an electrolyte layer disposed between the first and second electrodes. In the first electrode, a first collector is provided with one of a positive electrode active material layer and a negative electrode active material layer. In the second electrode, a second collector is provided with the other one of the positive and negative electrode active material layers. The first and second collectors have thicknesses such that when a conductor from outside penetrates at least two cells and a short circuit is formed between two cells via the conductor, shorted portions of the first and second collectors are fused by the heat generated by the current before the temperature of the cells reaches a predetermined value so that the short circuit is blocked.

Abstract: The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

Abstract: A battery is provided with a plurality of unit cells each having a tab, a bus bar connecting the tab of one of the plurality of unit cells and the tab of another one of the plurality of unit cells, and a plurality of welding points disposed on a center of gravity of an area, in which the bus bar and the tab are overlapped, or a vicinity thereof, and at least one position of line segments, radiately extending from the center of gravity, or a vicinity thereof, such that the bus bar and the tab are connected to one another at the plurality of welding points.

Abstract: A battery is provided with a plurality of unit cells each having a tab, a bus bar connecting the tab of one of the plurality of unit cells and the tab of another one of the plurality of unit cells, and a plurality of welding points disposed on a center of gravity of an area, in which the bus bar and the tab are overlapped, or a vicinity thereof, and at least one position of line segments, radiately extending from the center of gravity, or a vicinity thereof, such that the bus bar and the tab are connected to one another at the plurality of welding points.

Abstract: The positive electrode active material sintered body for a battery of the present invention is a positive electrode active material sintered body for a battery satisfying the following requirements (I) to (VII): (I) fine particles in a positive electrode active material are sintered to constitute the sintered body; (II) a peak pore diameter which provides a maximum differential pore volume value in a pore diameter range of 0.01 to 10 ?m in a pore distribution is 0.3 to 5 ?m; (III) a total pore volume is 0.1 to 1 cc/g; (IV) an average particle diameter is not less than the peak pore diameter and not more than 20 ?m; (V) any peak, which provides a differential pore volume value of not less than 10% of the maximum differential pore volume value, is not present on a smaller pore diameter side than the peak pore diameter in the pore distribution; (VI) a BET specific surface area is 1 to 6 m2/g; and (VII) a full width at half maximum of a strongest X-ray diffraction peak is 0.13 to 0.2.

Abstract: The burned composite metal oxide of the present invention is a burned composite metal oxide which is porous and particulate and which is obtained by subjecting a slurry comprising at least one metal oxide (a), at least one metal compound (b) and a solvent to spray granulation to obtain granules, and burning the granules, the metal oxide (a) selected from the group consisting of a transition metal oxide and an oxide of a metal belonging to 3B, 4B and 5B of a periodic table, the metal compound (b) selected from the group consisting of an alkali metal compound and an alkali earth metal compound, wherein the metal oxide (a) and the metal compound (b) are sparingly soluble in the solvent; the burning is conducted after a heat-maintaining step of heating the granules obtained by the spray granulation at a temperature in a range of ±200° C.

Abstract: The present invention provides a composite material for positive electrodes of lithium batteries, which provides a lithium battery having excellent high rate electrical discharge characteristics, has a sufficiently secured diffusion passage for Li, and has high conductivity, a process for producing the same, as well as a positive electrode and a battery using the composite material for positive electrodes of lithium batteries. The present invention relates to a composite material for positive electrodes of lithium batteries, comprising composite particles containing positive electrode active material particles and fibrous carbons, wherein the composite particles have a form in which the positive electrode active material particles are supported by the fibrous carbons.

Abstract: A battery is provided with a plurality of unit cells each having a tab, a bus bar connecting the tab of one of the plurality of unit cells and the tab of another one of the plurality of unit cells, and a plurality of welding points disposed on a center of gravity of an area, in which the bus bar and the tab are overlapped, or a vicinity thereof, and at least one position of line segments, radiately extending from the center of gravity, or a vicinity thereof, such that the bus bar and the tab are connected to one another at the plurality of welding points.

Abstract: The present invention provides a bipolar battery made by using a polymer gel electrolyte or a liquid electrolyte in an electrolyte layer, which is highly reliable and prevents liquid junction (short circuit) caused by leak out of an electrolyte solution from the electrolyte part. The present invention provides a bipolar battery laminated, in series, with a plurality pieces of bipolar electrodes which is formed with a positive electrode on one surface of a collector, and a negative electrode on the other surface, so as to sandwich an electrolyte layer, characterized by being provided with a separator which retains the electrolyte later, and a seal resin which is formed and arranged at the outer circumference part of a part of the separator where the electrolyte is retained.

Abstract: A battery structure for improving a heat dissipating property and a vibration absorbing performance. The battery structure comprises a plurality of unit cell layers, each formed by alternately stacking a cathode active material layer formed on a surface of one collector, a separator for retaining an electrolyte and an anode active material layer formed on a surface of another collector. The battery structure also comprises a heat dissipating member disposed between at least one unit cell layer and another unit cell layer.

Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.4-acyl-2?,3?-didehyd-ro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Abstract: A bipolar battery includes: a bipolar electrode composed, by forming a positive electrode active material layer 12 an one surface of a current collector and forming a negative electrode active material layer 13 on the other surface; and a separator 14 composed to be stacked alternately with the bipolar electrode, wherein, in a single cell layer 15 composed by including the positive electrode active material layer 12, the separator 14 and the negative electrode active material layer 13, which are adjacent to one another, a thickness of the separator 14 is 0.68 times or more to less than 1.0 times a thickness of the positive electrode active material layer 12, and is 0.68 times or more to less than 1.0 times a thickness of the negative electrode active material layer 13.

Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.4-acyl-2?,3?-didehyd-ro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Abstract: The present invention provides a bipolar battery made by using a polymer gel electrolyte or a liquid electrolyte in an electrolyte layer, which is highly reliable and prevents liquid junction (short circuit) caused by leak out of an electrolyte solution from the electrolyte part. The present invention provides a bipolar battery laminated, in series, with a plurality pieces of bipolar electrodes which is formed with a positive electrode on one surface of a collector, and a negative electrode on the other surface, so as to sandwich an electrolyte layer, characterized by being provided with a separator which retains the electrolyte later, and a seal resin which is formed and arranged at the outer circumference part of a part of the separator where the electrolyte is retained.

Abstract: The disclosed invention is a bicyclo[4.2.1]nonane and its pharmaceutically acceptable salt or prodrug, and its composition and method of use to treat Flaviviridae (Hepacivirus, Flavivirus, and Pestivirus) infections in a host, including animals, and especially humans.

Abstract: The present invention provides a bipolar battery made by using a polymer gel electrolyte or a liquid electrolyte in an electrolyte layer, which is highly reliable and prevents liquid junction (short circuit) caused by leak out of an electrolyte solution from the electrolyte part. The present invention provides a bipolar battery laminated, in series, with a plurality pieces of bipolar electrodes which is formed with a positive electrode on one surface of a collector, and a negative electrode on the other surface, so as to sandwich an electrolyte layer, characterized by being provided with a separator which retains the electrolyte later, and a seal resin which is formed and arranged at the outer circumference part of a part of the separator where the electrolyte is retained.

Abstract: The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

Abstract: The present invention is directed to a compound, method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acylcytosine-1,3-dioxolane and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.